No products in the cart.
Rabbit Anti-LRSAM1 Antibody (CSB-PA751010ESR1HU)
Supplier: CUSABIO BIOTECH CO.
E3 ubiquitin-protein ligase LRSAM1Curated Antibody,Leucine-rich repeat and sterile alpha motif-containing protein 1 Antibody,LRSAM1 AntibodyMore alternative names for the antibody
CMT2P antibody|E3 ubiquitin protein ligase LRSAM1 antibody|E3 ubiquitin-protein ligase LRSAM1 antibody|EC 6.3.2.- antibody|FLJ31641 antibody|hTAL antibody|Leucine rich repeat and sterile alpha motif containing 1 antibody|Leucine rich repeat and sterile alpha motif containing protein 1 antibody|Leucine-rich repeat and sterile alpha motif-containing protein 1 antibody|LRSAM1 antibody|LRSM1_HUMAN antibody|OTTHUMP00000022174 antibody|OTTHUMP00000022175 antibody|RIFLE antibody|TAL antibody|Tsg101 associated ligase antibody|Tsg101-associated ligase antibody
Anti-LRSAM1 antibody (ab73113)
Anti-LRSAM1 antibody (ab73113)
Recommended applications: ELISA, WB, IHC
Recommended dilution: User optimized
Recommended protocols: check protocols
|Catalogue No.|| |
Recombinant human E3 ubiquitin-protein ligase LRSAM1 protein (1-290AA)
ELISA, WB, IHC
|Recommended dilution|| |
|Molecular weight|| |
Antigen Affinity Purified
Shipped at 4 Celcius Degree. Upon delivery aliquot and store at -20 Celcius Degree or -80 Celcius Degree. Avoid repeated freeze.
|Protein function|| |
E3 ubiquitin-protein ligase that mediates monoubiquitination of TSG101 at multiple sites, leading to inactivate the ability of TSG101 to sort endocytic (EGF receptors) and exocytic (HIV-1 viral proteins) cargos (PubMed:15256501). Bacterial recognition protein that defends the cytoplasm from invasive pathogens (PubMed:23245322). Localizes to several intracellular bacterial pathogens and generates the bacteria-associated ubiquitin signal leading to autophagy-mediated intracellular bacteria degradation (xenophagy) (PubMed:23245322, PubMed:25484098). .
|Protein tissue specificity|| |
Highly expressed in adult spinal cord motoneurons as well as in fetal spinal cord and muscle tissue. .
|Involvement in disease|| |
Charcot-Marie-Tooth disease 2P (CMT2P) [MIM:614436]: An axonal form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Neuropathies of the CMT2 group are characterized by signs of axonal degeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy. Nerve conduction velocities are normal or slightly reduced. . Note=The disease is caused by mutations affecting the gene represented in this entry.
|Protein sequence and domain|| |
The coiled coil domains interact with the SB domain of TSG101.; The PTAP motifs mediate the binding to UEV domains.; The LRR domain is necessary and sufficient for localization to bacterial targets.; The RING domain is required for ubiquitination.
|Protein post-translational modifications|| |
Ubiquitination promoted by PHF23 leads to proteasomal degradation. .
|Protein cellular localization|| |
Cytoplasm . Note=Displays a punctuate distribution and localizes to a submembranal ring (PubMed:15256501). Localizes to intracellular bacterial pathogens (PubMed:23245322). .
AntibodyPlus provides antibody trial sample for your own antibody validation and collects antibody reviews.
CUSABIO BIOTECH CO.
|Product type|| |
There are no reviews for this product yet.
By submitting a review, get following benefits:
1. Receive $50 ABcoins as credit for each review.
2. First trial sample order will be fully refunded as credit.
3. Have a chance to win a $50 amazon gift card!
There is no extra validation for this product yet.
Check other extra validated antibodies below: